Sun Pharmaceutical Industries Brokerage: Bank of America Merrill Lynch Rating: Buy Target: Rs 855 Rationale: They expect consensus upgrades to drive re-rating, driven by sustenance of Taro product increase aiding margins, synergies from URL and DUSA acquisitions and resumption of Caraco sales.
Bharat Forge Brokerage: I-SEC Rating: Buy Target: Rs 237 Rationale: Valuations are factoring in most of the concerns and present an opportunity to gain from a revival in the automobile sector in FY15.
Tata Motors Brokerage: CLSA Rating: Buy Target: NA Rationale: JLR's product transformation story is likely to gain pace and the rising share of SUVs in luxury auto sales. Improving china penetration will drive market share gains for JLR.
Mahindra and Mahindra Brokerage: Religare Rating: Buy Target: Rs 1100 Rationale: Strong volume outperformance and pricing action in the months ahead should help improve the margin trajectory.